1.Go AS, Mozaffarian D, Roger, VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013;127(1):e6–e245.
2.Schwamm, LH, Ali, SF, Reeves, MJ, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals. Circ Cardiovasc Qual Outcomes 2013;6:543–9.
3.Rimmele, DL, Thomalla, G. Wake-up stroke: clinical characteristics, imaging findings, and treatment option – an update. Front Neurol 2014;5:35.
4.Cheng, B, Brinkmann, M, Forkert, ND, et al. Quantitative measurements of relative fluid-attenuated inversion recovery (FLAIR) signal intensities in acute stroke for the prediction of time from symptom onset. J Cereb Blood Flow Metab 2013;33(1):76–84.
5.The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333(24):1581–7.
6.Lindsberg, PJ, Sairanen, T, Strbian, D, Kaste, M. Current treatment of basilar artery occlusion. Ann N Y Acad Sci 2012;1268:35–44.
7.Fisher, CM. The herald hemiparesis of basilar artery occlusion. Arch Neurol 1988;45(12):1301–3.
8.Brosinski, CM. Implementing diagnostic reasoning to differentiate Todd’s paralysis from acute ischemic stroke. Adv Emerg Nurs J 2014 Jan–Mar; 36(1): 78–86.
9.Ropper, AH. Convulsions in basilar artery occlusion. Neurology 1988;38(9):1500–1.
10.Schonewille, WJ, Wijman, CA, Michel, P, et al. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol 2009;8(8):724–30.
11.Barber, PA, Zhang, J, Demchuk, AM, Hill, MD, Buchan, AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56(8):1015–20.
12.Smith, EE, Fonarow, GC, Reeves, MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 2011;42(11):3110–15.
13.Levine, SR, Khatri, P, Broderick, JP, et al. Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms. Stroke 2013;44(9):2500–5.
14.Jauch, EC, Saver, JL, Adams, HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44(3):870–947.
15.Lees, KR, Bluhmki, E, von Kummer, R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375(9727):1695–703.
16.Fonarow, GC, Zhao, X, Smith, EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014;311(16):1632–40.
17.Zinkstok, SM, Engelter, ST, Gensicke, H, et al. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke 2013;44(4):1080–4.
18.Saver, JL, Barsan, WG. Swift or sure?: The acceptable rate of neurovascular mimics among IV tPA-treated patients. Neurology 2010;74(17):1336–7.
19.Hand, PJ, Kwan, J, Lindley, RI, Dennis, MS, Wardlaw, JM. Distinguishing between stroke and mimic at the bedside: the brain attack study. Stroke 2006;37(3):769–75.
20.White-Bateman, SR, Schumacher, HC, Sacco, RL, Appelbaum, PS. Consent for intravenous thrombolysis in acute stroke: review and future directions. Arch Neurol 2007;64:785–92.
21.Chiong, W, Kim, AS, Huang, IA, Farahany, NA, Josephson, SA. Inability to consent does not diminish the desirability of stroke thrombolysis. Ann Neurol 2014;76(2):296–304.
22.Gadhia, J, Starkman, S, Ovbiagele, B, Ali, L, Liebeskind, D, Saver, JL. Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis. Stroke 2010;41:300–6.
23.Rost, NS, Masrur, S, Pervez, MA, Viswanathan, A, Schwamm, LH. Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke. Neurology 2009;73(23):1957–62.
24.Cucchiara, BL, Jackson, B, Weiner, M, Messe, SR. Usefulness of checking platelet count before thrombolysis in acute ischemic stroke. Stroke 2007;38(5):1639–40.
25.Walter, S, Kostopoulos, P, Haass, A, et al. Point-of-care laboratory halves door-to-therapy-decision time in acute stroke. Ann Neurol 2011;69:581–6.
26.Lin, SY, Tang, SC, Tsai, LK, et al. Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use. Eur J Neurol 2014;21(10):1285–91.